



We Build
Advanced, Affordable and Accessible
Surgical Robotic Solutions

SS Innovations International, Inc.
Company Presentation
June 2025
Nasdaq: SSII



Forward-Looking Statements

Forward-Looking Statements

This Presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by our forward-looking statements. Examples of forward-looking statements include projected financial information, statements of our plans and objectives for future operations and statements concerning proposed new products and services. In some cases, you can identify forward-looking statements by the use of terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential" and other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements. Actual events or results may differ materially. We undertake no obligation to update any of the forward-looking statements after the date of this Presentation to conform them to actual results. Please refer to the risk factors described in the "Risk Factors" section and other sections included in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the SEC.

No Offering of Securities

No offer is made by this Presentation to invest in the Company or to purchase any of its securities. Any offer to make such an investment or purchase and such investment or purchase will be made only pursuant to definitive offering documentation furnished by the Company.

Snapshot of SS Innovations

- We develop innovative, **differentiated surgical robotic technologies**, highlighted by our:
 - proprietary, **gold-standard surgical robotic system, "SSi Mantra 3"**;
 - **comprehensive suite of surgical instruments**, which support a variety of surgical procedures, including **robotic cardiac surgery**; and
 - AI- and XR-driven **imaging, training and simulation platform**.
- Our vision: to continuously improve and deploy our **technologically-advanced, cost-effective** surgical robotic systems, while maintaining **affordability** and **accessibility** for the benefit of a larger segment of patients globally.
- We are backed by a team of leading **surgical robotics experts** and seasoned medical technology executives.
- We are a rapidly growing American company with Indian roots, **expanding globally** and preparing for our strategic entry into **Europe** and the **United States**.

4,000+

Multi-Specialty Surgeries

93

SSI Mantra Systems Installed

9

Surgical Specialities

75

Hospitals

100+

Validated Surgical Procedures

16


Tele Surgeries

200+


Robotic Cardiac Surgeries

0


Complications
Injuries
Mortalities



Snapshot of SS Innovations (Continued)



Headquarters	Gurugram, India
US Office	New York, NY
Employees (4/15/25)	378
Year Founded	2019
Year Merged with Avra Medical	2023
Ticker	SSII
Exchange	Nasdaq
Shares Out (5/13/25)	193.6 mm
Recent Price (5/29/25)	\$6.03
Market Cap (5/29/25)	\$1.2 bn
Insider Ownership (4/14/25)	76.5%



¹ Estimated data as of May 2025

Investment Highlights and Agenda

- **Distinguished Leadership and Board** with Proven Track Record in Surgical Robotics Technology
- **Advanced, Surgical Robotics Technology Platform** Validated Clinically and Commercially
- **Differentiated Product Offering**, Including **Optimal Cost-Effectiveness** and **Cardiac Surgery Capabilities**
- **Large and Growing Addressable Market** with **Favorable Industry Tailwinds**
- **World-Class R&D** and **Manufacturing Facilities** to Support Growth
- Stronghold in India, **Global Expansion Underway** with **Near-Term Catalysts** Anticipated in the EU and US
- Early Innings of **Exponential Sales Growth, Expanding Margins** and Increasing Mix of **Recurring Revenue**
- Strategy to Deliver **Long-Term, Sustainable Growth**

Distinguished Leadership and Board with Proven Track Record in Surgical Robotics Technology



Sudhir Srivastava, MD, Founder, Chairman, CEO & Director

- Robotic Cardiac Surgeon
- Pioneered many of the world's first robotic cardiac procedures
- 40+ years of surgical experience; trained 350+ clinical teams
- 1,400+ robotic cardiac surgeries
- Trained 350+ clinical teams
- University of British Columbia, University of Chicago, Alliance Hospital
- Owns 117,158,445 shares, or 58.9% of SSII shares outstanding¹



Frederic Moll, MD, Vice-Chairman

- Former Chief Development Officer, J&J Medical Devices
- Founder, Intuitive Surgical, Hansen Medical, Auris Health
- Founder Partner, Sonder Capital Management
- Board Member, Procept Biorobotics, Neptune Medical, Moon Surgical
- Former Board Member, Shockwave Medical, Restoration Robotics, Intersect ENT
- Widely regarded as the "Father of Surgical Robotics"
- Owns 20,335,045 shares, or 10.2% of SSII shares outstanding¹

INTUITIVE

hansen
MEDICAL

auris
SURGICAL ROBOTICS

Johnson & Johnson

Distinguished Leadership and Board with Proven Track Record in Surgical Robotics Technology



Vishwajyoti Srivastava, MD, Chief Executive Officer - APAC

- Columbia University
- International College of Robotic Surgeons




Tim Paul Adams, Board Member

- Regional Operating Officer, Ascension
- Former Regional CEO, Tenet Healthcare
- Chairman, Tennessee Hospital Association



Arvind Palaniappan, Interim Chief Financial Officer

- Chartered Accountant, Institute of Chartered Accountants, England and Wales
- Principal, Trogon Consulting
- Various Executive Positions, Accenture Solutions (India)



Somashekhar SP, MD, Board Member

- Robotic Surgeon
- Global Director, Aster International Institute of Oncology



Barry Cohen, COO - Americas

- Co-Founder, CEO and Director, Avra Medical Robotics
- Former Director and President, Synalloy Corp.
- Former Chairman of the Board, Wolverine Technologies, Inc.



Dr. Mylswamy Annadurai, Board Member

- Former Director, Indian Space Research Organization (ISRO)

Advanced Surgical Robotics Technology Platform

SSi Mantra 3




Intellectual Property

Granted
5 Utility patents
30 Design patents

69 Filed patent applications

Trademarks
Filed: 124; Registered: 53



Improved Patient Experience
Reduced Variabilities
Lower Per Procedure Costs

Advanced Surgical Robotics Technology Platform

SSi Mantra 3 – Surgical Command Center



Ergonomic Open-Faced
Console

Large 3D 4K Monitor

Large 2D Touch Monitor
for System Controls and
DICOM access

Lightweight Magnetic
Hand Controls Design


Head Tracking Safety
Feature

Digital Ergonomics
Control

Tele Surgery and Tele
Proctoring Enabled

Advanced Surgical Robotics Technology Platform

SSi Mantra 3 – Patient Side Robotic Arm Carts



Modular Robotic Carts

Freedom of Patient
Docking

3/4/5
Patient Cart
Connectivity

Absolute Stability
Parking Locks

Smaller Individual Cart
Footprint

Advanced Touch Screen
Controls

Multi-Specialty Use
Including
Cardiac Surgery

Advanced Surgical Robotics Technology Platform

SSi Mantra 3 – Vision Cart



Large 3D 4K Monitor
for OR Staff

Inbuilt Multimedia
Recording, Playback and
Streaming

Articulating Endoscope
and Camera System

Pre-Operative Guidance
Software

UPS Backup

E-Stop Safety Features

Standard
5 Robotic Arms
Connectivity Control Box

Advanced Surgical Robotics Technology Platform

SSi Mudra – Multi Specialty Robotic Instruments



40+
Types of
Instruments

7 Degrees of Freedom
Articulating Robotic
Instruments


10 Use
Life Cycle
per Instrument

20+
Cardiac Specialty
Instruments

Novel Instrument:
**Automated Coronary
Anastomotic
Connector***




Novel Instrument:
Multi-Fire Clip Applier*




Advanced Instruments:
**Selicut
Harmonic**



Advanced Instruments:
**ExpertSeal
Vessel Sealer**



Advanced Instruments:
**Anastoflex
Stapler**



Advanced Surgical Robotics Technology Platform

SSi Mudra – Cardiac Robotic Instruments



Robotic Cardiac Surgery Potential

Only company in the world **actively advocating** for robotic cardiac surgery

Untapped market potential in **automated coronary artery bypass surgery**


190+ complex robotic cardiac surgeries performed with the SSI Mantra

20+


Cardiac Specialty Instruments*




Cardiac Stabilizer



Valve Retractor - Long



Valve Retractor - Short



Black Diamond Forceps




Small Bipolar Forceps



Micro Scalpel




Debaquey Forceps



Fine Tip Scissors



Cautery Hook




Cautery Spatula




Cadiere Forceps




Long Tip Forceps



Small Titanium Clip Applier



Resano Forceps



Round Tip Scissors

Advanced Surgical Robotics Technology Platform

SSi Maya – Enhancing Surgical Capabilities with Mixed Reality and AI Enabled Technologies



SSi Guru

XR Tele Proctoring System

- Mixed Reality Headset
- Portable 3D Surgery Viewer
- Interactive Virtual Screens
- CDSCO Approved
- Virtual Tele Illustration Feature
- Proctored over 1200 miles under 400 ms latency

AR Smart Glasses*



3D Visualization System

- 3D HD 1080p vision
- Variable IPD adjustments
- Direct from endoscope video signal processing
- IMU based head tracking

Cognitive Skill Simulator*

A different approach to train surgeons

- Overlaid instruments tracking
- Guided procedure steps
- Trains cognition and muscle memory
- Enhancing motor skills through repetition
- Console and VR based learning system



Mixed reality-powered and AI-enabled technologies for better training, visualization, and simulation for the entire surgical team.

Advanced Surgical Robotics Technology Platform

World's First Robotic Cardiac Tele Surgery



Feb 2025 - SSI HQ - Gurugram, India

177 miles

Manipal Hospital - Jaipur, India

Mar 2025 - SSI HQ - Gurugram, India

1,245 miles

Aster CMI Hospital - Bengaluru, India

Advanced Surgical Robotics Technology Platform

SSI Mantra M – Tele Surgery Mobile Unit

Enhances remote surgical access and empowers underserved communities through tele-surgery, surgical education, mentoring, and real-time data insights.

Unveiled at the Second Global SS Innovations Multi-Specialty Robotic Surgery Conference 2025, on March 8th in India

Decentralizing and Democratizing access to Robotic surgery to global communities

Equipped with the SSI Mantra 3 Surgical Robotic System and MantraSync Tele-Surgery platform


SSI MANTRAM



Advanced Surgical Robotics Technology Platform

SSI Sutra – Centralized Data Registry System

Centralized digital platform designed to document, analyze, and streamline surgical workflows, clinical data, and procedural insights across the SSI Mantra robotic ecosystem.




Differentiated Product Offering, Including Optimal Cost-Effectiveness and Cardiac Surgery Capabilities

SS Innovations Advantages versus Leading Brand

Feature	Benefit	SSII	Leading Brand
Surgeon Command Center			
Open Face Console	Ergonomic posture optimizes surgeon comfort and performance	Yes	No
Large 3D 4K Monitor	High resolution 3D video for accurate depth perception	Yes	No
Large 2D Touch Controls Monitor	Large secondary visual interface to access system controls and data	Yes	No
Hand and Foot Controls Visibility	Open console feature enables clear visibility of physical controls for better precision	Yes	No
Instant Operating Room Visibility	Better communication with support staff and patient access	Yes	No
Lightweight Magnetic, Ergonomic Hand Controls	Newer technology with completely free range of motions without mechanical restrictions	Yes	No
Hand Controls Safety	Disables system controls when surgeon disengages hand controls	Yes	No
Patient Side Console			
Modular Carts	Ease of multi-quadrant accessibility	Yes	No
5 Arm System	Enabling instrumentation for surgeon's use in complex cases (cardiac)	Yes	No
Robotic Arm Configuration Flexibility	Use of 3-5 arms based on surgical and cost requirements	Yes	No
Vision Cart			
Large 3D 4K Monitor for Staff	High resolution 3D video for accurate depth perception for surgical assistance	Yes	No
In-Built Recording System	Records intra-operative surgery videos for data analysis and training	Yes	No
Articulating 3D Endoscope	Reduces the need for multiple rigid endoscopes	Yes	No
Instruments			
Cardiac Stabilizer	Instrument used for beating heart totally endoscopic coronary artery bypass surgeries	Yes	No
Articulating Reusable Vessel Sealer	Wristed and cost effective	Yes	No
Enabling Technologies			
Tele-Surgery	Enabling true remote access surgery to provide gold-standard robotic surgery from experts	Yes	No
3D XR DICOM	Enabling mixed reality technologies to visualize patient data	Yes	No
Other			
Relative Cost Effectiveness	Approximately 1/3rd the cost of competing systems	Yes	No
Cardiac Surgery Capabilities	Full spectrum robotic cardiac surgery, including beating heart TECAB with SSI stabilizer	Yes	Limited

Large and Growing Addressable Market with Favorable Industry Tailwinds

Market Expected to Increase from **\$5.1 Billion in 2024** with a **CAGR of 11.7%** to **\$15.5 Billion in 2034**¹



Geography	No. of Multiport Surgical Robotic Systems
North America	6000+
South America	120+
Europe	1500+
Japan	570+
China	350+
India	290+
Australia	70+
Africa	10+
Middle East	50+

Large and Growing Addressable Market with Favorable Industry Tailwinds

Accelerated Global Adoption of Robotic Surgery

Macro Trends

- Large under-penetrated markets such as India, China, and other high-growth economies with rising incomes
- Increase in healthcare spending and health insurance in under-penetrated markets

Technology

Innovation and enhanced capabilities make next-generation systems versatile across a broad spectrum of surgeries

Demographics

Aging global population driving increased need for surgical interventions

Disease Burden

Growing incidence of chronic and lifestyle diseases

Workforce Challenges

Helps address Increasing shortage of trained healthcare workers, by reducing labor intensity across each care episode

Economics

Improved economics for providers and payers

Patient Benefits

Reduced patient trauma, shorter recovery times, and enhanced patient outcomes


Surgeon Benefits

Ergonomic systems reduce staff fatigue and enhanced training pathways across varying skill level improves adoption


Hospital Benefits

Improved resource utilization, increased revenue, reduced cost with lower complication rates and shorter lengths of stay

Global Surgical Robotics Market*



Surgeries Conducted by Robotic Systems is Expected to Grow 4x by 2030



SSI aims to accelerate access to surgical robotics in underserved regions of the world

Large and Growing Addressable Market with Favorable Industry Tailwinds

Access to Robotic Surgery Remains Limited

Benefits of Robotic Surgery

Greater Precision

Minimal Blood Loss

Faster Recovery

10x Magnified 3D vision

Less Pain and Discomfort

Reduced Surgeon Fatigue

Smaller Incisions on Patients

Reduced Risk of Infection

In the 20 Years Since Launch of Robotic Surgery, Access Remains Limited:

Installed base largely limited to the US, EU and Japan

7 billion people have access to only 5% of installed systems

Intuitive Surgical has ~10% of the global soft tissue procedure market

Key Challenges of Existing Systems

High cost of acquisition and implementation

Absence of trained personnel

Unattractive economics for hospitals with lower volumes

Lack of versatility and adaptability of systems and limited systems with multi-specialty capabilities

Key Population and Healthcare Data

	Share of Population	No. of Hospitals	No. of Hospital Beds (thousands)	Share of Da Vinci Systems
USA	4.2%	6,120	917	59.4%
EU	5.6%	15,000	2,300	18.8%
China	17.7%	36,570	8,000	4.0%
India	17.8%	70,000	1,858	1.6%
RoW	54.7%	37,310	4,925	16.2%

Source: Secondary Market Research

Large and Growing Addressable Market with Favorable Industry Tailwinds

Unmet Needs and Accessibility Challenges Support Our Foundational Market in India

~1.4 Billion
Population

~70,000 Hospitals
in India

~1.9 Million
Beds

~26,000
Large Hospitals
With **150+** beds

700+
Medical Colleges

~60,000
Robot Assisted Surgeries have been
performed in India as of 2024

Since 2002,
Only **296 Surgical Robotic Systems***
for a population of 1.458 billion

~1500
Trained Robotic Surgeons in India

Of which

4,000+
Robot Assisted Surgeries performed
in India as of May 2025 on the
SSI Mantra

93
Surgical Robotic Systems are
SSI Mantra
(1/3rd the Installation base)

700+
Robotic Surgeons trained on the
SSI Mantra

World-Class R&D and Manufacturing Facilities to Support Growth

Cost-Effective, State-of-the-Art R&D and Manufacturing Facilities in India

R&D, Manufacturing,
Assembly, and
Operations in Gurgaon, Delhi
**National Capital Region
(India)**

Proximity to
**New Delhi
International airport**
with excellent
connectivity with all
parts of the world



75,000 Sq ft space
spread over three floors

Manpower as of 4/15/25:
378




20 Systems per month
Current Production Capacity

Manufacturing expansion
plans with inhouse
CNC and Tooling
machines




Stronghold in India, Global Expansion Underway with Near-Term Catalysts Anticipated in the EU and US

SS Innovations vs Competitor Installations in India*



Company	Launch Date
SS Innovations	August 2022
Medtronic	September 2021
CMR	October 2019
Intuitive	December 2002



Stronghold in India, Global Expansion Underway with Near-Term Catalysts Anticipated in the EU and US

Global Expansion – Quality and Regulatory Approvals


India CDSCO	EN ISO 13485	Nepal	Ecuador
Guatemala	Philippines	Indonesia	Ukraine
Colombia	Sri Lanka	US FDA	EU CE

In 2024, SS Innovations generated approximately **92%** of its revenue from **India**.

We expect the percent of total revenue coming from the **rest of the world** to significantly expand from **8%** in 2024.

Stronghold in India, Global Expansion Underway with Near-Term Catalysts Anticipated in the EU and US

EU CE Mark - Estimated Timeline



Notified body - Szutest, Germany

Stronghold in India, Global Expansion Underway with Near-Term Catalysts Anticipated in the EU and US

US FDA – Estimated Timeline

Current Stage



FDA Q Sub
Regulatory
Strategy
Feedback,
Biocompatibility,
Reprocessing
2024

De Novo
Classification
Request dossier
preparation*




De Novo
Submission
July 2025

De Novo Initial
Feedback
(Deficiency letter)
30 Days

Market Clearance
Mar/April 2026***

Clinical Trials
US/ OUS**

Early Innings of Exponential Sales Growth, Expanding Margins and Increasing Mix of Recurring Revenue



¹Recurring revenues from sales of instruments, accessories and services.

Strategy to Deliver Long-Term, Sustainable Growth

Emphasis on Organic Growth

Focus on Large Multi-Specialty Hospitals

- Secure Initial Placements
- Expand # of Physicians using Mantra 3
 - Increase System Utilization at Each Hospital
- Place Additional Systems at Each Hospital (Go Deeper)

Target **Leading Surgeons and Thought Leaders** to Raise Awareness and Encourage Widespread Adoption

- Indian Medical Advisory Board
- International Advisory Board
 - Medical Conferences
- Robotic Surgery Training Programs
- Strategic Partners (e.g., Johns Hopkins)

Communicate **Benefits**

- Advanced Technology
 - Low Cost
 - Ease of Training
- Improved Patient Outcomes
- Differentiated Features (e.g., Cardiac)

Continuously Improve and Innovate Our Top-Tier Robotics Platform through **New Product Development** and **Enhanced Technology**.

Maintain **Stronghold in India**, Grow in **Select Underserved Countries** with Low Penetration and Cost Barriers, and Pursue **Established Markets**.

Conclusions

- **Distinguished Leadership and Board** with Proven Track Record in Surgical Robotics Technology
- **Advanced, Surgical Robotics Technology Platform** Validated Clinically and Commercially
- **Differentiated Product Offering**, Including **Optimal Cost-Effectiveness** and **Cardiac Surgery Capabilities**
- **Large and Growing Addressable Market** with **Favorable Industry Tailwinds**
- **World-Class R&D** and **Manufacturing Facilities** to Support Growth
- Stronghold in India, **Global Expansion Underway** with **Near-Term Catalysts** Anticipated in the EU and US
- Early Innings of **Exponential Sales Growth, Expanding Margins** and Increasing Mix of **Recurring Revenue**
- Strategy to Deliver **Long-Term, Sustainable Growth**

Financial Summary

SS Innovations Statement of Operations	Twelve Months Ended		Three Months Ended	
	December 31, 2023	December 31, 2024	March 31, 2024	March 31, 2025
Revenue	5,875,314	20,649,528	3,637,693	5,120,610
Gross Profit	725,528	8,452,366	728,182	1,087,208
Gross margin	12.3%	40.9%	20.0%	21.2%
Operating income (loss)	(20,273,984)	(18,975,962)	(9,832,319)	(5,921,853)
Net income (loss)	(20,878,292)	(19,151,197)	(9,841,753)	(5,681,353)
Diluted EPS	\$(0.14)	\$(0.11)	\$(0.06)	\$(0.03)
Diluted shares	152,069,825	181,203,673	181,609,691	188,599,859
Balance Sheet	March 31, 2025			
Cash	15,873,217			
Current assets	47,619,943			
Total assets	63,456,961			
Current liabilities	14,996,713			
Long term debt	-			
Total stockholders' equity	40,554,290			

Investor Contact:

EQUITY GROUP

Kalle Ahl, CFA

(303) 953-9878

kahl@theequitygroup.com



www.ssinnovations.com

investors@ssinnovations.org